Gene Doping: The Hype and the Harm

Pediatric Clinics of North America

Volumn 57, Issue 3, 2010, Pages 719-727

  McKanna, Trudy A ^a   Toriello, Helga V ^a  

^a SPECTRUM HEALTH   (United States)

Author keywords

Athletic performance; Detection; Gene therapy; Mutations; Polymorphisms

Indexed keywords

BONE MORPHOGENETIC PROTEIN; ENDORPHIN; ERYTHROPOIETIN; LIPOSOME; MYOSTATIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); PLASMID DNA; SOMATOMEDIN C; VASCULOTROPIN;

ADENO ASSOCIATED VIRUS; ADENOVIRUS; AUTOIMMUNE DISEASE; BLOOD VISCOSITY; BONE STRESS; CELL TRANSFER; DUCHENNE MUSCULAR DYSTROPHY; ELECTROPORATION; EX VIVO GENE TRANSFER; FEVER; GENE DOPING; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE MUTATION; GENE OVEREXPRESSION; GENE THERAPY; GENE TRANSFER; GENE VECTOR; GERM LINE GENE THERAPY; HEART FAILURE; HUMAN; IMMUNE RESPONSE; IN VIVO GENE TRANSFER; INFLAMMATION; LASER; MUSCLE MASS; MUTAGENESIS; NONHUMAN; RETROVIRUS; REVIEW; RISK FACTOR; RNA INTERFERENCE; SOMATIC GENE THERAPY; STROKE; TENDON STRESS; TISSUE REPAIR; TRANSGENICS; TUMOR GROWTH; ULTRASOUND;

ANIMALS; ATHLETIC PERFORMANCE; BONE MORPHOGENETIC PROTEINS; DOPING IN SPORTS; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC ENHANCEMENT; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MUTATION; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 77953600554     PISSN: 00313955     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcl.2010.02.006     Document Type: Review

References (27)

1. Scollay R. Gene therapy. A brief overview of the past, present and future. Ann N Y Acad Sci 2001, 953:26-30.
2. World Anti-Doping Agency The 2010 prohibited list: international standard. Montreal, Canada; September 19, 2009 Available at:, Accessed January 26, 2010. http://www.wada-ama.org/Documents/World_Anti-Doping_Program/WADP-Prohibited-list/WADA_Prohibited_List_2010_EN.pdf.
3. World Anti-Doping Agency WADA St. Petersburg declaration. St. Petersburg, Russia; June 11, 2008 Available at:, Accessed December 29, 2009. http://www.wada-ama.org/Documents/Science_Medicine/Scientific%20Events/WADA_StPetersburg_Declaration_2008.pdf.
4. Baoutina A., Alexander I.E., Rasko J.E.J., et al. Developing strategies for detection of gene doping. J Gene Med 2008, 10:3-20.
5. Wells D.J. Gene doping: the hype and the reality. Br J Pharmacol 2008, 154:623-631.
6. Gatzidou E., Gatzidou G., Theocharis S. Genetically transformed world records: a reality or in the sphere of fantasy?. Med Sci Monit 2009, 15(2):RA41-RA47.
7. Azzazy H.M.E., Mansour M.M.H., Christenson R.H. Gene doping: of mice and men. Clin Biochem 2009, 42:435-441.
8. Harridge S.D.R., Velloso C.P. IGF-1 and GH: potential use in gene doping. Growth Horm IGF Res 2009, 19:378-382.
9. Minunni M., Scarano S., Mascini M. Affinity-based biosensors as promising tools for gene doping detection. Trends Biotechnol 2008, 26(5):236-243.
10. Varlet-Marie E., Audran M., Ashenden M., et al. Modification of gene expression: help to detect doping with erythropoiesis-stimulating agents. Am J Hematol 2009, 84(11):755-759.
11. Harridge S.D.R., Velloso C.P. Gene doping. Essays Biochem 2008, 44:125-138.
12. Evans C.H., Ghivizzani S.C., Robbins P.D. Orthopedic gene therapy in 2008. Mol Ther 2009, 17(2):231-244.
13. Wells D.J. Gene doping: possibilities and practicalities. Med Sport Sci 2009, 54:166-175.
14. Gaffney G.R., Parisotto R.P. Gene doping: a review of performance-enhancing genetics. Pediatr Clin North Am 2007, 54:807-822.
15. Lunde I.G., Ekmark M., Zaheer A.R., et al. PPAR-delta expression is influenced by muscle activity and induces slow muscle properties in adult rat muscles after somatic gene transfer. J Physiol 2007, 582:1277-1287.
16. Barton-Davis E.R., Shoturma D.I., Musaro A., et al. Viral mediated expression of insulin-like growth factor I blocks the aging-related loss of skeletal muscle function. Proc Natl Acad Sci U S A 1998, 95:15603-15607.
17. Unal M., Unal D.O. Gene doping in sports. Sports Med 2004, 34(6):357-362.
18. Rodino-Klapac L.R., Haidet A.M., Kota J., et al. Inhibition of myostatin with emphasis on follistatin as a therapy for muscle disease. Muscle Nerve 2009, 39(3):283-296.
19. Schuelke M., Wagner K.R., Stolz L.E., et al. Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med 2004, 350:2682-2688.
20. Wolfarth B., Bray M.S., Hadberg J.M., et al. The human gene map for performance and health-related fitness phenotypes: the 2004 update. Med Sci Sports Exerc 2005, 37:881-903.
21. Ahmetov I.I., Rogozkin V.A. Genes, athlete status and training- an overview. Med Sport Sci 2009, 54:43-71.
22. Schulze J.J., Lundmark J., Garle M., et al. Doping test results dependent on genotype of UGT2B17, the major enzyme for testosterone glucuronidation. J Clin Endocrinol Metab 2008, 93(7):2500-2506.
23. Lippi G., Longo U.G., Maffulli N. Genetics and sports. Br Med Bull 2010, 93:27-47.
24. Raper S.E., Chirmule N., Lee F.S., et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 2003, 80:148-158.
25. Legge M., Fitzgerald R., Jones L. An alternative consideration in drug testing in elite athletes. N Z Med J 2008, 121(1278):73-77.
26. Murray T.H. Reflections on the ethics of genetic enhancement. Genet Med 2002, 4(6):27S-32S.
27. Miah A. Rethinking enhancement in sport. Ann N Y Acad Sci 2006, 1093:301-320.